BridgeBio Pharma ROA 2018-2025 | BBIO
Current and historical return on assets (ROA) values for BridgeBio Pharma (BBIO) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| BridgeBio Pharma ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2025-03-31 |
$-0.67B |
$0.88B |
-81.84% |
| 2024-12-31 |
$-0.54B |
$0.92B |
-66.32% |
| 2024-09-30 |
$-0.44B |
$0.67B |
-61.39% |
| 2024-06-30 |
$-0.45B |
$0.79B |
-63.71% |
| 2024-03-31 |
$-0.54B |
$0.85B |
-84.26% |
| 2023-12-31 |
$-0.64B |
$0.55B |
-110.34% |
| 2023-09-30 |
$-0.61B |
$0.66B |
-101.83% |
| 2023-06-30 |
$-0.57B |
$0.50B |
-92.34% |
| 2023-03-31 |
$-0.43B |
$0.63B |
-59.86% |
| 2022-12-31 |
$-0.48B |
$0.62B |
-63.56% |
| 2022-09-30 |
$-0.49B |
$0.73B |
-57.36% |
| 2022-06-30 |
$-0.51B |
$0.86B |
-58.67% |
| 2022-03-31 |
$-0.60B |
$0.81B |
-64.52% |
| 2021-12-31 |
$-0.56B |
$1.01B |
-56.64% |
| 2021-09-30 |
$-0.54B |
$0.78B |
-58.47% |
| 2021-06-30 |
$-0.50B |
$1.08B |
-54.01% |
| 2021-03-31 |
$-0.52B |
$1.09B |
-59.60% |
| 2020-12-31 |
$-0.45B |
$0.70B |
-53.03% |
| 2020-09-30 |
$-0.40B |
$0.79B |
-48.51% |
| 2020-06-30 |
$-0.35B |
$0.91B |
-43.69% |
| 2020-03-31 |
$-0.29B |
$0.99B |
-51.44% |
| 2019-12-31 |
$-0.26B |
$0.63B |
-81.70% |
| 2019-06-30 |
$-0.16B |
$0.00B |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$7.324B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
